Journal Management System
 
Home  |   Add your Journal  |   Features  |   Journal List
Author Login | Reviewer Login | Editor Login
Search  

Medical Archives
Periodical of AVICENA, d.o.o., Sarajevo
Journal Home Page
ISSN: 0350-199X (Print)
ISSN: 1986-5961 (Online)
Language: [ English ]  
News / Announcements

  » Volume 68, Issue 4
      pp. 228-293
  » Volume 68, Issue 3
      pp. 156-222
  » Volume 68, Issue 2
      pp. 76-146
  » Volume 68, Issue 1
      pp. 4-70

 

Open Access

Original Research



Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight

Snjezana Milicevic.

Cited by (1)

Abstract
Introduction/Goal: Bladder wall thickness and bladder mass are higher in patients with subvesical obstruction caused by benign prostate enlargement (BPE) in compensated stage of the disease. The goal of the study was to determine changes of bladder detrusor in patients suffering from benign prostatic hyperplasia (BPH) during tamsulosin treatment. The study was open, prospective and multi-centric. Material and methods: The material in this study was composed of 20 patients, aged > 45 years, with the present lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia, who had not been treated for the previous 3 months. The inclusive criteria also included the value of International Prostate Symptom Score (IPSS) ≥8 points, post-void residual urine volume (PVR) <100 ml and prostate specific antigen (PSA) <4 ng/ml. After the end of the trials that were necessary for the introduction of the patients in the study, the patients started taking tamsulosin in a daily dosage of 0.4 mg, and the evaluation parameters during the research were measured at time intervals of 4, 12 and 24 weeks. The evaluation parameters were primary and secondary. The primary parameter included ultrasound estimated bladder weight (UEWB), while the secondary included determination of the blood pressure values (RR) and pulse frequency (PF), of total International Prostate Symptom Score (T-IPSS), a part of IPSS that related to the storage symptoms (I-PSS), a part that related to the voiding symptoms (O-IPSS), quality of life determination (IPSS-QoL), ultrasound estimation of prostate volume (VP) and the quantity of post-void residual urine volume (PVR), along with the determination of the number and strength of adverse reactions. Results: During the introduction of the patients in the trial, the arithmetic mean of UEWB was 65 g, of PVR 43 ml, VP 35 ml, of total T-IPSS 15.6 points, of I-IPSS 6.9 points, of O-IPSS 8.7 points, and of IPSS-QoL 3.6 points. During the four-week, twelve-week and twenty-four-week checkups, the values were the following: the arithmetic mean of UEWB 36, 39 and 28 grams, of PVR 26, 29 and 21 ml, of T-IPSS 8.3, 6.4 and 5.0 points, of IPSS 3.8, 3.0 and 2.4 points, of O-IPSS 4.6, 3.4 and 2.6 points, of IPSS-QoL 1.7, 1.1 and 1.0 points and of VP 34 ml during the last control. The obtained results of this trial were processed by descriptive statistics (arithmetic mean and standard deviation) and analytical statistics by way of Student’s t-test for dependant (paired) samples, with the comparison made between the obtained results with the zero checkup and four-week checkup, and subsequently the comparison between four-week and twelve-week checkup, twelve-week and twenty-four week checkup, and the zero checkup and the twenty-four week checkup. Adverse drug reactions (libido and ejaculation problems 5% and headache 5%) were mild and tolerant and did not require the interruption of the therapy. Conclusion: During a 24-week treatment of benign prostat

Key words: benign prostatic hyperplasia, urinary bladder, tamsulosin, ultrasonography, bladder wall thickness, ultrasound estimated bladder weight



REFERENCES
1. Roehrborn C, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, retik A, Vaughan E, Wein A (eds). Campbells Urology, 8th ed. Saunders: Philadelphia, 2002. pp 1297-1336.


2. Eckhardt MD, van Venrooji GE, Boon TA. Symptoms, prostate volume and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia. Urology. 2001; 58: 966-971.

[
DOI via Crossref]   


3. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004; 171: 1029-1035.

[
DOI via Crossref]   
[Pubmed]   


4. Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am. 1999; 83: 1213-1229.

[
DOI via Crossref]   


5. Barry MJ. Measuring and assessing BPH in population group. In Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Textbook of Benign Prostatic Hyperplasia, 2nd edn. London: TaylorFrancis, 2005:141-50.


6. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D. Identification of alpha 1-adrenoreceptor subtypes present in the human prostate. Life Sci. 1994; 54: 1595-1605.

[
DOI via Crossref]   


7. Lepor H, Tang R, Kobayashi S et al. Localization of the alpha 1A-adrenoreceptor in the human prostate. J Urol. 1995; 154: 2096-2099.

[
DOI via Crossref]   


8. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha 1A-1, alpha 1B and alpha 1D-adrenoreceptors in hyperplastic and non-hyperplastic hum, and prostate. J Urol. 1999; 161: 635-640.

[
DOI via Crossref]   


9. Miyashita H, Kojima M, Miki T. Ultrasonic measurement of bladder weight as a possible predictor of cute urinary retention in men with lower urinary tract symptoms suggestive of benign prostate hyperplasia. Ultrasound Med Biol. 2002; 28: 985-990.

[
DOI via Crossref]   


10. Hakenberg OW, Linne C, Manseck A, Wirth MP. Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourol Urodyn. 2000; 19: 585-593.

[
DOI via Crossref]   


11. Kojima M, Inui E, OchiaiA, Naya Y, Ukimura O, Watanabe H. Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction. Urology. 1996; 47: 942

[
DOI via Crossref]   


12. Oelke M, Bachmann A, Descazeaud A, Emberton M, et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Guidelines EAU; 2012.


13. Keong TF. Decision making in the management of benign prostatic enlargement and the role of transabdominal ultrasound. IJU. 2010; 17: 974-979.


14. Manieri C, Carter SSC, Romano G, trucchi A, Valentini M, Tubaro A. The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. J urol. 1998;159:761-765.

[
DOI via Crossref]   


15. Kojima M, Inui E, Ochiai A, Naya Y, Ukimura O, Watanabe H. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement od bladder weight. J Urol. 1997; 157:476-479.

[
DOI via Crossref]   


16. Walsh PC: Benign prostatic hyperplasia, in Walsh PC, Retic AB, Stamey TA, and Vaughan ED Jr (Eds): Capmbells Urology, 6th ed. Philadelphia, WB Saunders, 1992. pp 1007-1027


17. Oelke M, Hofner K, Wiese B, Grunewald V, Jonas U. Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. World J Urol. 2002; 19: 443-452.

[
Pubmed]   


18. Uluocak N, erdemir F, Parlaktas BS, Caglar MK, Hasiloglu Z, Etikan I. Bladder wall thickness in healthy school-aged children. Urology. 2007; 69: 763-766.

[
DOI via Crossref]   
[Pubmed]   


19. Blatt AH, Titus J, Chan L. Ultrasound measurement of bladder wall thickness in the assessment of voiding dysfunction. J urol 2008;179:2275-9.

[
DOI via Crossref]   
[Pubmed]   


20. Lekskulchai O, Dietz HP. Detrusor wall thickness as a test for detrusor overactivity in women. Ultrasound Obstet Gynaecol. 2008; 32: 535-539.

[
DOI via Crossref]   
[Pubmed]   


21. Kojima M, Inui E, Ochiai A, Ukimura O, Watanabe H. Quantitative evaluation of estimated bladder weight (EWB) in men with infravesical obstruction using transabdominal sonography- a preliminary study. Neurourol. Urodyn. 1995; 14: 453


22. Kokima Y, Sasaki S, Imura M, Kubota Y, Hayasi Y, Kohri K. Correlation between expression of alpha 1 adrenoreceptor subtype mRNA and severity of lower urinary tract symptoms or bladder outlet obstruction in benign prostatic hyperplasia patients. BJU Int. 2010; 107: 438-442.

[
DOI via Crossref]   
[Pubmed]   


23. Schwinn DA. The role of alpha 1 adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 2001; 88: 27-34.

[
DOI via Crossref]   
[Pubmed]   


24. Aganovic D, Hadziosmanovic O, Prcic A, Kulovac B. The Significance of the Influence of Aging and Intravesical Obstruction Caused by Benign Prostatic Enlargement on Detrusor Impairment. Med Arh. 2012; 66(3): 185-189.

[
DOI via Crossref]   
[Pubmed]   


25. Aganovic D, Prcic A, Hadziosmanovic O, Hasanbegovic M. Does the Combination of Intravesical Prostatic Protrusion and Bladder Outlet Obstruction Number Increase Test Accuracy According to BenignProstatic Obstruction at the Individual Level. Acta Inform Med. 2012; 20(3): 160-166.

[
DOI via Crossref]   


26. Aganovic D, Hasanbegovic M, Prcic A, Kulovac B, Hadziosmanovic O. Which is a Better Indicator of Bladder Outlet Obstruction in Patients with Benign Prostatic Enlargement - Intravesical Protrusion of Prostate or Bladder Wall Thickness? Med Arh. 2012; 66(5): 324-328.

[
DOI via Crossref]   
PMid:23097971

This Article Cited By the following articles

Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin
Aging Male 2014; (): 1.

1
 

How to Cite this Article
Pubmed Style

Milicevic S. Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight . Med Arh. 2012; 66(6): 391-395. doi:10.5455/medarh.2012.66.391-395



Web Style

Milicevic S. Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight . www.scopemed.org/?mno=28937 [Access: September 21, 2014]. doi:10.5455/medarh.2012.66.391-395



AMA (American Medical Association) Style

Milicevic S. Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight . Med Arh. 2012; 66(6): 391-395. doi:10.5455/medarh.2012.66.391-395



Vancouver/ICMJE Style

Milicevic S. Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight . Med Arh. (2012), [cited September 21, 2014]; 66(6): 391-395. doi:10.5455/medarh.2012.66.391-395



Harvard Style

Milicevic, S. (2012) Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight . Med Arh, 66 (6), 391-395. doi:10.5455/medarh.2012.66.391-395



Turabian Style

Milicevic, Snjezana. 2012. Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight . Medical Archives, 66 (6), 391-395. doi:10.5455/medarh.2012.66.391-395



Chicago Style

Milicevic, Snjezana. "Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight ." Medical Archives 66 (2012), 391-395. doi:10.5455/medarh.2012.66.391-395



MLA (The Modern Language Association) Style

Milicevic, Snjezana. "Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight ." Medical Archives 66.6 (2012), 391-395. Print. doi:10.5455/medarh.2012.66.391-395



APA (American Psychological Association) Style

Milicevic, S. (2012) Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight . Medical Archives, 66 (6), 391-395. doi:10.5455/medarh.2012.66.391-395



Submit your manuscript
Register
Abstracting & Indexing
Instructions for Authors
Editorial Board
Aims & Scope
About this Journal
Sign up for TOC

ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Snjezana Milicevic
on IndexScholar Fulltext
on Google
on Google Scholar
Article Statistics
 Viewed: 924
Downloaded: 214
Cited: 1




 




» For Authors




Become Reviewer


» Login Area






Follow ScopeMed on Twitter

ScopeMed Home
Job Opportunities/Service Offers
About ScopeMed
Terms & Conditions
Privacy Policy
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of SAGEYA Publishing for Scientific Publications. Copyright © ScopeMed® International Medical Journal Management and Indexing System.